Abstract
As new protocols are developed and treatment plans change, the demand for higher numbers of donor stem cells for patients has increased. This is especially true for non-myeloablative transplants where a higher cell dose may be needed to assure engraftment. There is a concern for safety in this donor population that elevated white blood cell counts may lead to altered blood flow kinetics, cause shortness of breath, decreased cerebral blood flow, and contribute to cardiac ischemia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
